Randomized controlled prospective study on treatment of mild COVID-19 with Qinghua Bihui Granules

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2200006038

Enrollment

Unknown

Registered

2022-05-26

Start date

2022-04-15

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

experimental group:Western medicine basic treatment + Qinghua Bihui Granules

control group:Western medicine basic treatment

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: The mild diagnosis of COVID-19 in accordance with the Novel Coronavirus Diagnosis and Treatment Protocol for Pneumonia (Trial Version 9) published by the NHC; The patient was older than 18 years; Signed informed consent.

Exclusion criteria

Exclusion criteria: Pregnant and lactating women; Patients allergic to Chinese medicine or allergic constitution of this project; Patients with malignant tumor, liver cirrhosis, chronic renal failure (uremic stage), blood system diseases, HIV and other serious underlying diseases; Patients with long-term use of hormones, immunosuppressants and other drugs; Who suffered from severe mental illness or were unable to cooperate with the study.

Design outcomes

Primary

Measure	Time frame
Nucleic acid conversion rate;Nucleic acid turning negative time;	—

Secondary

Measure	Time frame
Tongue and pulse survey of TCM;TCM diagnosis syndrome elements;TCM syndrome scoring Scale;	—

Countries

china

Contacts

Public ContactHongze Wu

yihuihn@163.com18970256865

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026